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Abstract 
Attention-deﬁcit/hyperactivity disorder (ADHD) is highly heritable and the most common neu- 
rodevelopmental disorder in childhood. In recent decades, it has been appreciated that in a 
substantial number of cases the disorder does not remit in puberty, but persists into adulthood. 
Both in childhood and adulthood, ADHD is characterised by substantial comorbidity including 
substance use, depression, anxiety, and accidents. However, course and symptoms of the disor- 
der and the comorbidities may ﬂuctuate and change over time, and even age of onset in child- 
hood has recently been questioned. Available evidence to date is poor and largely inconsistent 
with regard to the predictors of persistence versus remittance. Likewise, the development of 
comorbid disorders cannot be foreseen early on, hampering preventive measures. These facts 
call for a lifespan perspective on ADHD from childhood to old age. In this selective review, we 
summarise current knowledge of the long-term course of ADHD, with an emphasis on clinical 
symptom and cognitive trajectories, treatment effects over the lifespan, and the development 
of comorbidities. Also, we summarise current knowledge and important unresolved issues on 
biological factors underlying different ADHD trajectories. We conclude that a severe lack of 
knowledge on lifespan aspects in ADHD still exists for nearly every aspect reviewed. We en- 
courage large-scale research efforts to overcome those knowledge gaps through appropriately 
granular longitudinal studies. 
© 2019 Radboud University Medical Center. Published by Elsevier B.V. 
This is an open access article under the CC BY license. 
( http://creativecommons.org/licenses/by/4.0/ ) 
1. Introduction 
Attention-deﬁcit/hyperactivity disorder (ADHD) is a neu- 
rodevelopmental condition that typically starts during 
childhood or early adolescence and is thought to follow a 
trait-like course. The clinical disorder is deﬁned by age- 
inappropriate levels of inattention and/or hyperactivity- 
impulsivity interfering with normal development, or 
functioning, of a person. Although ADHD carries the stigma 
of being a consequence of modern lifestyle, the ﬁrst 
mentioning of the syndrome dates back to the late 18th 
century ( Faraone et al., 2015 ). Historically, ADHD was de- 
scribed mainly in school-age boys ( Still, 2006 ). Later, it was 
recognised that many girls have similar problems – yet 
often remain unrecognised and, consequently, undiag- 
nosed. During the past decades, it has been demonstrated 
that ADHD is common in all countries studied ( Fayyad 
et al., 2017; Polanczyk et al., 2014 ), and that it seriously 
affects the productivity, life expectancy, and quality of life 
throughout the lifespan of patients ( Erskine et al., 2013 ). 
Importantly, it took until the late 20th century before it 
could convincingly be shown that ADHD also exists in adults, 
and that continuity exists from childhood to adulthood 
( Wood et al., 1976 ) calling for a lifespan perspective on the 
Developmental trajectories of ADHD 1061 
disorder, embracing clinical course and presentation as well 
as according research on the underlying neurobiology. 
As discussed in detail in this review, the clinical presen- 
tation of ADHD is very heterogeneous, with a wide spectrum 
of severity and symptoms that partially overlap with other 
conditions. In fact, ADHD symptoms can be observed tran- 
siently not only in psychiatric disorders, but also in somatic 
diseases and physiological states, such as after sleep de- 
privation or during over-exhaustion ( Poirier et al., 2016 ). 
This complex clinical picture has led to a need to deﬁne 
core diagnostic attributes of ADHD, such as age of onset, 
continuity of symptoms and their appearance under various 
circumstances, symptom counts, and exclusion criteria. Al- 
though the diagnostic criteria have been revised multiple 
times, the core clinical description of ADHD has remained 
essentially unchanged during several decades. In the latest 
version of the Diagnostic and Statistical Manual of Mental 
Disorders (DSM-5), it is simply stated that “ADHD begins in 
childhood” and that it often manifests itself in pre-school 
age ( APA, 2013 ). This apparent simpliﬁcation does not imply 
that every person with ADHD will have an identical clinical 
picture, or that impairment is linearly dependent on symp- 
tom counts or age of onset. 
Unfortunately, the ﬁelds of research on childhood and 
adulthood ADHD have operated in relative isolation, mainly 
due to a historical hiatus between child/adolescent and 
adult psychiatry. However, the need for a lifespan perspec- 
tive is becoming increasingly apparent, and is enhanced by 
the voices of patients and their representatives (see e.g. the 
Textbox below). In this review, we present selected litera- 
ture to summarise the current knowledge on ADHD from a 
developmental, lifespan perspective. Preventive measures 
as well as age-speciﬁc diagnostics and interventions require 
knowledge about the highly dynamic changes in ADHD pre- 
sentation from childhood to adulthood, and our review of 
the current state of knowledge is intended to provide re- 
searchers and clinicians with an overview on the trajectory 
of this disorder. We focus on phenotypic changes across the 
lifespan, age of onset issues (also covering the recent dis- 
cussion on adult onset ADHD), lifespan aspects of comorbid- 
ity, pharmacological and non-pharmacological treatment, 
as well as aspects of disease outcome with and without 
treatment. In addition, we summarise knowledge on cogni- 
tive and neuroimaging changes during life with the disorder 
and touch on lifespan aspects in the study of genetic and 
environmental risk factors for the disorder as well as the in- 
terplay of those two. Subsequent to these reviews, we point 
out existing knowledge gaps and identify needs for further 
research. 
Textbox . The patient per specti ve – contributed by Andrea Bil- 
bow, President of ADHD-Europe and Founder and Chief Exec- 
utive of the Attention Deficit Disorder Information and Support 
Service (ADDISS) 
Despite considerable advances in our understanding of 
ADHD, patients still experience signiﬁcant problems 
gaining access to the support and treatment they need. 
Service user groups are established in most European 
countries. One of these groups, ADHD-Europe ( http: 
//www.adhdeurope.eu ), aims to advance the rights 
of, and advocate on every level throughout Europe, 
for people affected by ADHD and comorbid conditions, 
helping them reach their full potential. ADHD-Europe 
plays a critical role in promoting awareness of ADHD 
and evidence-based treatments, facilitate the efforts 
of national and regional ADHD support groups, and ad- 
vocate to European Institutions for the delivery of ap- 
propriate services for children, adolescents, and adults 
with ADHD. 
Currently, the experience of service users is that 
they are often directed towards services that do not 
recognise the speciﬁc problems related to ADHD. This 
is a particular problem for adults with ADHD, although 
the quality and availability of child services also varies 
considerably across different countries and regions. 
Patients often feel there is nowhere to go for help 
with ADHD-related problems. In most cases, adult so- 
cial care does not yet cater for ADHD. At the same 
time, old age, learning disability, and mental health 
teams often do not consider ADHD as a mental health 
problem, which then falls between the cracks, with no 
service provision available. The lack of support con- 
tributes to people with ADHD experiencing more se- 
vere problems with age. When faced with challenges, 
they may feel overwhelmed and develop or exacer- 
bate comorbid problems such as anxiety, depression, 
and drug use, which then complicate ADHD. Much more 
work around social care and support is required. 
Even where there are health-care services for ADHD, 
the approach is often to use drugs alone without pro- 
viding the additional psychosocial support that is re- 
quired. In most cases, it is not enough to just see some- 
one and give a prescription. Health-care profession- 
als need to consider the environmental circumstances 
of each individual, and clinicians need to think “what 
more can I do for that person”. Practical support can 
come in many ways, but the key is to have a single 
person coordinating the treatment package – one who 
is aware of the individual circumstances and difﬁcul- 
ties faced by people being treated for ADHD and can 
provide practical support as required. 
Medication is viewed as an essential tool to ensure 
that other supports become effective. However, medi- 
cation often does not fully control all of the symptoms 
of ADHD, and most importantly, does not build skills. 
Organisational skills can improve with medication – be- 
ing less distracted and more able to stay on task and 
get things done – but people still need daily life skills. 
For example, someone may remain overwhelmed by 
tasks such as how to tidy up a room, how or organ- 
ise and complete paperwork, and how to plan ahead 
for the successful completion of tasks and ideas. 
Scaffolding and support for people with ADHD is 
complex and specialised. One of the problems is that 
support is often offered for short periods, such as 
3 months, but then they are on your own. Lifelong 
scaffolding and support may be required. To ﬁll the 
gap in service provision, a considerable amount of 
necessary practical and psychosocial support is cur- 
rently provided by the voluntary sector. One approach 
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advocated by ADHD-Europe is to invest in the voluntary 
sector to provide the support services required, rather 
than rely on good-will of patient support groups. This 
is particularly important as the role of the voluntary 
sector is limited in what they can do due to lack of 
funding. 
2. Phenotype of ADHD across the lifespan –
course and changes in presentation over time 
ADHD is deﬁned as a persistent, trans-situational pattern 
of inattention and/or hyperactivity-impulsivity that is inap- 
propriate to the developmental stage and interferes with 
functioning or development ( APA, 2013 ). Importantly, ADHD 
symptoms as such do not reﬂect a manifestation of opposi- 
tional behaviour, deﬁance, hostility, or failure to understand 
tasks or instructions, although such problems are often seen 
to accompany ADHD. Meta-analysis of longitudinal follow-up 
studies of children with ADHD suggests that at least 15% con- 
tinue to meet full diagnostic criteria for ADHD by the age of 
25 years, and a further 50% meet criteria for ADHD in par- 
tial remission, with persistence of subthreshold symptoms 
still causing impairment ( Faraone et al., 2006 ). However, 
there is considerable heterogeneity in those estimates, as 
e.g. more recent estimates of persistence into young adult- 
hood for children and adolescents diagnosed with DSM-IV 
combined type ADHD in Europe are much higher (up to 80%) 
( Cheung et al., 2015a; van Lieshout et al., 2016b ), perhaps 
reﬂecting the severity of cases included in these studies, 
and/or the use of informant- rather than self-ratings. 
Prevalence rates for ADHD in children range around 
6.5% ( Polanczyk et al., 2007 ). Estimates for adults vary 
widely across studies, but average around 2.5–3.4% in meta- 
analysis ( Fayyad et al., 2007; Simon et al., 2009 ). Fayyad 
et al. (2017) cite estimates ranging between 1.4 and 3.6%. 
Such variation is almost certainly due to methodological 
differences in the way the diagnostic criteria are applied, 
including the childhood onset of symptoms, the methods 
to capture the 18 behavioural symptoms used to deﬁne 
the condition, and the application of impairment criteria 
( Willcutt, 2012 ). Deﬁnitions of impairment are a particular 
issue, because ADHD symptoms are known to be continually 
distributed throughout the population, with no clear separa- 
tion between those with and without ADHD ( Mulligan et al., 
2008 ). The disorder is therefore deﬁned by high levels of 
symptoms when they interfere with or reduce the quality of 
social, academic, or occupational functioning (NICE, 2013 ). 
This might also at least in part underlie the discrepancy 
between cross-sectional, epidemiological studies showing 
adult ADHD prevalence rates almost as high as childhood 
prevalence rates ( Fayyad et al., 2017 ), and longitudinal 
samples that suggest adult prevalence rates to be much 
lower ( Faraone et al., 2015 ). 
Characteristic changes occur in the proﬁle of ADHD 
symptoms throughout development. Very young children 
are more likely to display externalising symptoms such as 
hyperactive-impulsive behaviour, while in middle childhood 
inattentive symptoms become more apparent, and by late 
adolescence and in adulthood it is inattention that tends 
to persist, while there is a decline in the more objective 
signs of (motor) hyperactivity ( Francx et al., 2015b; Will- 
cutt et al., 2012 ). Emotional lability, however, becomes a 
growing burden, which can even dominate the clinical pic- 
ture. It is this changing proﬁle and instability in the bal- 
ance of symptoms presenting throughout development that 
led to disbanding of the DSM-IV ADHD subtypes of predom- 
inantly inattentive, predominantly hyperactive-impulsive, 
and combined subtypes; those are now referred to as clin- 
ical presentations in DSM-5. Although many adults present 
with predominantly inattentive symptoms, this is not to 
mean they have the same rate of hyperactive or impulsive 
symptoms compared to age-matched controls. Persistence 
of more overt hyperactivity-impulsivity is seen at higher 
rates especially among those with some of the most se- 
vere comorbid problems related to ADHD, such as substance 
abuse and antisocial behaviour ( Huntley et al., 2012 ). 
Sex differences in the rates of ADHD are prominent but 
change throughout development in both clinical and com- 
munity settings ( Kooij et al., 2010; Larsson et al., 2011 ). 
Typically, in child and adolescent clinics, around 80% of 
ADHD cases are male, whereas in adult clinics, the propor- 
tion of males is closer to 50% ( Kooij et al., 2010 ). One possi- 
ble reason for the predominance of males in child clinics is 
the greater hyperactivity-impulsivity levels they show com- 
pared to girls, who are more likely to display predominantly 
inattentive symptoms and less overt disruptive behaviours. 
Several lines of evidence support this notion. For example, 
an epidemiological survey of childhood ADHD found the ra- 
tio of male to female cases was 7.0 for the hyperactive- 
impulsive subtype, 4.9 for the combined subtype, and 3.0 
for the inattentive subtype of ADHD. However, there was 
still a greater percentage of boys with ADHD of any sub- 
type (3.6%) compared to girls (0.85%). This is consistent 
with mean scores for ADHD symptoms in general popula- 
tion samples that show that, as a group, boys have higher 
levels of both inattentive and hyperactive-impulsive symp- 
toms than girls. Interestingly, by late adolescence, while 
sex differences in inattention appear to remain, the level 
of hyperactivity-impulsivity in boys declines to the level of 
the girls ( Larsson et al., 2011 ), suggesting that the expres- 
sion of core ADHD symptoms is more similar across the sexes 
in the adult population. In addition to sex differences in the 
expression of core ADHD symptoms, it is likely that comor- 
bid problems contribute to different referral rates for boys 
compared to girls, with boys presenting with more external- 
ising disruptive behaviours and learning problems. In adults, 
it is well known that women are more likely to seek help for 
mental health problems, impacting on referral rates, but 
levels of comorbid disorders appear to be similar in both 
men and women with ADHD ( Biederman et al., 2004 ). 
While diagnostic criteria for ADHD originate from diag- 
nosis of children, the currently used diagnostic criteria, 
when applied to adults, are also well-validated and there- 
fore appear to work well in the classiﬁcation of clinical 
cases of the disorder ( Asherson et al., 2010 ). Validation of 
the diagnostic criteria also requires the prediction of func- 
tional and clinical impairments (NICE, 2018 ). Yet, most clin- 
ical experts are aware of a broader expression of symp- 
toms commonly reported by adults with ADHD ( Asherson 
et al., 2016; Kooij et al., 2010 ) falling into three main 
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Fig. 1 Theoretical developmental trajectories of ADHD across 
the lifespan. Details are given in the text. 
categories: age-adjusted expression of core ADHD symp- 
toms, behaviours reﬂecting problems with self-regulation 
(executive functions), and additional problems that are 
commonly seen in ADHD. Age-adjusted ADHD core symp- 
toms include some items in DSM-5 ( APA, 2013 ) and e.g. 
internal restlessness, ceaseless unfocused mental activity, 
and a difﬁculty focusing on conversations. Problems with 
self-regulation are e.g. problems with controlling impulses, 
switching attention, regulating emotional responses, initi- 
ating tasks, and problem-solving. Interestingly, while these 
are strongly correlated with the core ADHD symptoms of 
inattention and hyperactivity-impulsivity, they do not cor- 
relate strongly with neuropsychological tests of executive 
or top-down cortical control ( Barkley, 2010; Barkley and 
Fischer, 2011 ), suggesting that, like core ADHD symptoms, 
they result from deﬁcits across multiple neural networks 
and cognitive processes. The additional problems seen in 
many adults include sleep problems and low self-esteem 
( Kooij et al., 2010 ). Furthermore, a study that carefully se- 
lected adult ADHD cases with no evidence for a comorbid 
disorder nevertheless found high rates of general mental 
health symptoms, such as subthreshold anxiety and depres- 
sion ( Skirrow and Asherson, 2013 ). 
3. Age of onset and current discussion on 
adult onset of ADHD 
As pointed out above, ADHD has always been viewed as a 
childhood-onset condition, although the ﬁrst age at onset 
criterion was not seen until the advent of DSM-III, which 
required onset prior to age 7 years ( APA, 1980 ). This thresh- 
old was raised to age 12 years in DSM-5 ( APA, 2013 ). Pa- 
tients, however, can meet symptom and impairment crite- 
ria at later ages. Sometimes, such cases are clearly due to 
brain injuries ( Fig. 1 ). If so, they are usually classiﬁed as 
“secondary” or “acquired” ADHD, to be distinguished from 
the childhood onset of ADHD discussed above ( Schachar 
et al., 2015 ). Longitudinal studies report a two-fold rela- 
tive risk of receiving a diagnosis of ADHD after mild trau- 
matic brain injury (TBI) ( Adeyemo et al., 2014 ); more severe 
brain trauma carries an even higher risk for ADHD ( Schachar 
et al., 2015 ). Overall, 15–50% of children with TBI develop 
secondary ADHD ( Schachar et al., 2015 ), which may be clin- 
ically indistinguishable from idiopathic ADHD. Because peo- 
ple with ADHD are at risk for accidents ( Dalsgaard et al., 
2015b ), ADHD may be a risk factor for head injuries ( Fann 
et al., 2002 ), although this has been difﬁcult to establish 
( Adeyemo et al., 2014 ). Nevertheless, it is possible that 
some patients with ADHD emerging subsequent to TBI had 
undiagnosed ADHD or subthreshold ADHD prior to their in- 
jury. 
In contrast to the well-established link between TBI and 
ADHD in adulthood, the idea that idiopathic ADHD arises, de 
novo , in adulthood is controversial. Three population stud- 
ies estimated high rates of adult-onset idiopathic ADHD, 
with a prevalence of 2.7% in New Zealand (NZ) ( Mofﬁtt 
et al., 2015 ), 10.3% in Brazil ( Caye et al., 2016 ), and 5.5% in 
the United Kingdom (UK) ( Agnew-Blais et al., 2016 ). The au- 
thors concluded that ADHD can onset in adulthood and that 
the adult-onset form of the disorder is categorically dis- 
tinct from the childhood-onset form. Yet these conclusions 
were premature. All three studies had some serious limi- 
tations ( Faraone and Biederman, 2016 ). Firstly, the age of 
the adults in the studies from Brazil and the UK was only 18 
to 19 years, so these studies provide no information about 
most of the adult period. Secondly, in all three studies, the 
rates of childhood-onset adult ADHD were much lower than 
expected ( Fayyad et al., 2017 ), suggesting that many of the 
childhood-onset cases may have been missed and misdiag- 
nosed as adult onset. Thirdly, all three studies suffer from 
the “false positive paradox”, which is the mathematical fact 
that, in the absence of perfect diagnostic accuracy, many of 
the diagnoses in a population study will be false positives. 
For example, if the prevalence of adult ADHD is 5%, and the 
false positive rate is only 5%, then half of the adult ADHD 
diagnoses in a population study will be false positives. Con- 
sistent with this idea, Sibley et al. (2017) concluded that 
adult onset of ADHD is rare, and that most people exceeding 
the symptom threshold for diagnosis are, on closer exami- 
nation, false positives. A fourth caveat for the three studies 
is that the distinction between childhood onset and adult- 
hood onset was confounded by the method of diagnosis: the 
former diagnoses were based on parent-report, whereas the 
latter were based on self-report. This is a problem, because 
another longitudinal study found that current symptoms of 
ADHD were under-reported by adults who had ADHD in child- 
hood and over-reported by adults who did not have ADHD 
in childhood ( Sibley et al., 2012 ). Moreover, considerable 
evidence suggests that, compared with informant-reports, 
self-reports of ADHD in adults are less reliable. The noise 
added by self-reports can be seen in the very low heritabil- 
ity for adult ADHD reported by the UK study (35%; Agnew- 
Blais et al., 2016 ), which contrasts with the higher heritabil- 
ity of adult ADHD from parent report or using diagnostic cri- 
teria ( Brikell et al., 2015 ). 
In all three studies, a participant was deﬁned as having 
“adult-onset” ADHD only if full diagnostic criteria for ADHD 
had not been achieved at prior assessments. In each study, 
however, many of the “adult-onset” cases had evidence of 
psychopathology in childhood. In the NZ study, in their child- 
hood years, the adult-onset ADHD group had more teacher- 
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rated symptoms of ADHD, were more likely to have been di- 
agnosed with conduct disorder (CD), and were more likely to 
have had a combined parent-teacher report of ADHD symp- 
tom onset prior to age 12 years ( Mofﬁtt et al., 2015 ). In 
the UK study, the adult-onset cases had signiﬁcantly ele- 
vated rates of ADHD symptoms, CD, and oppositional deﬁant 
disorder (ODD) in childhood ( Agnew-Blais et al., 2016 ). In 
the study from Brazil, only about a third of the adult-onset 
cases were free of ADHD and CD symptomatology in child- 
hood ( Caye et al., 2016 ). These population studies mirror 
retrospective reports from referred cases, in which many 
late adolescent and adult onset cases of ADHD had child- 
hood histories of psychopathology ( Chandra et al., 2016 ). 
Faraone and Biederman (2016) suggested that apparent 
cases of adult-onset ADHD are mostly due to the existence 
of subthreshold childhood ADHD. For example, a prospec- 
tive population study deﬁned “subthreshold ADHD” ( Fig. 1 ) 
as having three or more inattentive symptoms or three or 
more hyperactive-impulsive symptoms ( Lecendreux et al., 
2015 ). It found that new-onset cases of ADHD in adolescence 
were signiﬁcantly more likely to have had subthreshold 
ADHD at baseline. In subthreshold cases, the onset of symp- 
toms and impairment could be separated by many years, 
particularly among those with supportive internal resources 
(e.g., high intelligence) or supportive social environments. 
Given the issues discussed above, and until more evi- 
dence is available, it seems best to refer to the adult- 
onset cases reported by the studies from NZ, Brazil, and 
the UK as apparent adult-onset ADHD (AAOA). An urgent 
clinical question is whether stimulant treatment is appro- 
priate for AAOA. This issue has not yet been systematically 
assessed. From a clinical perspective, AAOA cases require 
extra caution. Although many show signiﬁcant functional 
impairments that require treatments for ADHD, some may 
have other disorders. 
In conclusion, substantial research indicates that a diag- 
nosable ADHD syndrome can arise in adulthood subsequent 
to brain injury. Other forms of apparent adult-onset ADHD 
may exist, but many of these are likely to have had undiag- 
nosed ADHD or subthreshold ADHD in youth. 
4. Comorbidity proﬁle changes over time 
To complicate matters further, not only does the clinical 
phenotype of ADHD change over the lifespan, but comor- 
bid conditions might dominate the initial appearance of a 
patient. This is of high relevance as ADHD patients fre- 
quently suffer from psychiatric and non-psychiatric comor- 
bid conditions, posing signiﬁcant clinical and public health 
problems ( Angold et al., 1999 ). Throughout the lifespan, 
the speciﬁc pattern of comorbidities changes substantially 
( Costello et al., 2003; Taurines et al., 2010 ): in short, while 
in children oppositional deﬁant disorder (ODD) and conduct 
disorder (CD) are the most prevalent comorbid conditions, 
substance use disorders (SUDs) become more and more of a 
problem during adolescence and even more so in adulthood. 
The comorbidity pattern of adult ADHD is highly diverse, 
and in addition to SUDs encompasses mood and anxiety dis- 
orders, antisocial personality disorder (ASP), sleep disor- 
ders ( Jacob et al., 2007 ), as well as many somatic diseases 
( Instanes et al., 2016 ). The developmental trajectory, risk 
factors, and moderators of this lifelong comorbidity course, 
however, are currently only poorly understood and require 
future longitudinal studies. Below, information on the most 
prominent ADHD comorbidities is given. 
4.1. Autism spectrum disorders, tics, and 
learning disorders 
ADHD and symptoms of autistic spectrum disorders (ASDs) 
often co-exist, as 20–50% of children with ADHD also meet 
criteria for ASDs ( Rommelse et al., 2011 ). Several studies 
have shown social deﬁcits, peer relationship, and empa- 
thy problems to be common in ADHD, and accordingly, the 
DSM-5 ﬁnally allows a comorbid diagnosis of ADHD and ASD. 
The ADHD-ASD comorbidity has mainly been studied in chil- 
dren; a review and meta-analysis, however, support its ex- 
istence also in adults ( Hartman et al., 2016 ). Recent data 
from a large, register-based study from Sweden suggest that 
the comorbidity has its roots in shared genetic/familial fac- 
tors ( Ghirardi et al., 2017 ). Tic disorders occur in up to 
3–4% of the population ( Robertson et al., 2009; Roessner 
et al., 2011 ) and are seen in 10 to 20% of children with 
ADHD ( Cohen et al., 2013; Steinhausen et al., 2006 ). Over 
the course of years, tic severity typically peaks between 
8 and 12 years of age. The natural history of tics usually 
shows a marked decline during adolescence ( Cohen et al., 
2013 ). Population studies suggest that intellectual disabil- 
ity may be more common (up to 5–10 times) in ADHD than 
in children without ADHD ( Simonoff et al., 2007 ). About 25–
40% of all patients with ADHD have major reading and writ- 
ing difﬁculties, and many show co-existing language disor- 
ders ( Sciberras et al., 2014; Willcutt et al., 2012 ). Similarly, 
there is a considerable overlap between ADHD and disor- 
ders of arithmetical skills ( Hart et al., 2010; Rapport et al., 
1999 ). As for ASD, hardly any information is yet available on 
the lifespan trajectories of ADHD with such comorbidities. 
4.2. Rule-breaking behaviours 
The comorbidity of ADHD with antisocial behaviours is of 
particular societal relevance, as ADHD seems to convey an 
increased risk for violence and incarceration especially in 
the context of such comorbidity ( Rosler et al., 2004 ). In 
children and adolescents, both clinical and epidemiological 
studies show a high prevalence of comorbidity of ADHD with 
ODD/CD, ranging from 25% up to 80% (median odds ratio 
(OR): 10) in different studies. ODD and CD predict a more 
severe clinical symptomatology, more severe functional im- 
pairments, higher persistence of ADHD into adulthood, and 
worse outcome of the disorder. They also mediate the risk 
for the development of other problems, such as substance 
use and depression ( Burke et al., 2002; Hill, 2002 ). Comor- 
bid ODD in childhood seems to also increase the risk for 
CD/ASP and depression in ADHD later in life, and comor- 
bid CD does even more ( Biederman et al., 2008; Mannuzza 
et al., 2004 ). Increased impulsivity may be an important 
risk factor within the ADHD group for these negative out- 
comes ( Retz and Rosler, 2009; Storebo and Simonsen, 2016 ). 
However, ADHD-affected children without these comorbidi- 
ties may also develop antisocial behaviours later in life 
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( Jensen et al., 1997; Loeber et al., 1995; Mannuzza et al., 
2004 ). SUDs and environmental variables might be impor- 
tant moderators in this, although this has yet to be formally 
established. 
4.3. Substance use disorders 
Another (related) issue of importance in ADHD across the 
lifespan is the liability to develop addictions. The earlier 
onset and increased use of tobacco, alcohol, and illicit sub- 
stances in adolescents with ADHD compared to controls has 
been demonstrated in various studies, and a high preva- 
lence of drug abuse or dependency (9–40%) is also reported 
in adulthood ( Buchmann et al., 2009; Jacob et al., 2007; 
Mannuzza et al., 1993; Milberger et al., 1997 ). A meta- 
analysis of cohort studies conﬁrmed that childhood ADHD 
signiﬁcantly increases the risk for nicotine use in middle 
adolescence (OR: 2.36, 1.71–3.27) and the risk for alcohol 
use disorder during young adulthood (OR: 1.35, CI: 1.11–
1.64) ( Charach et al., 2011 ). This meta-analysis also sug- 
gested that children with ADHD may have an elevated risk 
for cannabis use and psychoactive substance use as young 
adults, but signiﬁcant heterogeneity exists between studies, 
and the association with drug use disorder was highly inﬂu- 
enced by a single study. As another meta-analysis showed, 
controlling for comorbid disorders (particularly CD) substan- 
tially weakened the association between ADHD and SUDs; 
in fact, it could not be conﬁrmed that ADHD increases the 
risk for SUDs beyond the effects of CD/ODD ( Serra-Pinheiro 
et al., 2013 ). Looked at from the other side, in adult pa- 
tients suffering from alcohol abuse, 30–70% suffered from 
childhood ADHD, and 15–25% still displayed the disorder as 
adults. 
4.4. Mood and anxiety disorders 
Adult ADHD is signiﬁcantly comorbid with anxiety disorders 
(up to 25%; median OR: 3.0) and major depression (5–20%; 
median OR: 5.5). Although these disorders are among the 
most common comorbidities of ADHD, especially in adoles- 
cents ( Meinzer et al., 2013 ) and adults ( Jacob et al., 2007 ), 
surprisingly little is known about the developmental trajec- 
tories of such comorbidity. As mentioned above, ODD/CD 
seem to be associated with later-life affective disorders; 
also, depressive and anxious symptoms during childhood and 
adolescence go along with increased risk for adult-life de- 
pression (as do general risk factors for depression), although 
often no such antecedents can be found in adult ADHD with 
depression. Rather, childhood ADHD itself seems to be a 
risk factor for the later development of depression, which 
can be reduced by e.g. methylphenidate treatment ( Chang 
et al., 2016 ). 
4.5. Disruptive mood dysregulation disorder and 
bipolar disorder 
An issue of increasing interest in research and clinic is the 
presence of extreme and uncontrolled emotional and mood 
changes in both children and adults with ADHD. Indeed, in 
DSM-5, problems with emotion regulation are listed as char- 
acteristic features of ADHD that support the diagnosis. Emo- 
tional dysregulation and ADHD are known to share genetic 
risks ( Merwood et al., 2014 ). In adult ADHD, emotional dys- 
regulation occurs also in the absence of comorbid disorders 
( Skirrow and Asherson, 2013 ), is an independent predictor 
of impairment ( Barkley and Fischer, 2010; Skirrow and Ash- 
erson, 2013 ), and responds to both stimulants and atomox- 
etine ( Moukhtarian et al., 2017 ). In some cases, specialist 
referral is advised to ensure accurate diagnosis, because 
the problems may be complex and predictive of particu- 
lar adverse outcomes ( Sobanski et al., 2010; Stringaris and 
Goodman, 2009 ). Comorbidity with bipolar disorder and bor- 
derline personality disorder both need to be considered in 
adults, since ADHD may co-exist with these conditions, but 
may also mimic them in the presence of severe emotional 
dysregulation ( Asherson et al., 2016 ). Cross-sectional epi- 
demiological studies as well as family-based studies show 
that there is increased comorbidity between bipolar disor- 
der and current or lifetime ADHD; mutual comorbidity rates 
are around 20% ( Kessler et al., 2006 ). The developmen- 
tal trajectories of this comorbidity are unclear, however, 
since bipolar disorder is rare in pre-adolescents, even when 
severe irritability and anger are prominent in this group 
( Brotman et al., 2006 ). The new DSM-5 diagnosis “disrup- 
tive mood dysregulation disorder (DMDD)” for children up to 
age 8 years exhibiting persistent irritability, intolerance to 
frustration, and frequent episodes of extreme behavioural 
dyscontrol captures those symptoms, yet the course of this 
syndrome into full-blown bipolar disorder is far from estab- 
lished. Importantly, most of the DMDD patients also meet 
criteria for ADHD. 
5. Treatment and response to treatment 
over time – pharmacological and 
non-pharmacological treatments 
The continuity of treatment of ADHD across the lifespan is 
an issue that still receives too little attention. Especially the 
transition from adolescence to adulthood, which is accom- 
panied by a transition from child and adolescent psychiatric 
clinics to adult psychiatry, is problematic; many patients are 
lost to follow up at that point. At every age, recommended 
treatment of ADHD should be multimodal, including psycho- 
education, pharmacotherapy, and disorder-oriented psy- 
chotherapy, including training, cognitive-behavioural ther- 
apy, and family or couple therapy if needed ( Faraone et al., 
2015; Kooij et al., 2010 ; NICE, 2018 ). 
Pharmacological treatments with the indication for ADHD 
are traditionally divided into two groups: stimulants and 
non-stimulants. Methylphenidate and amphetamines are 
the stimulant options, and atomoxetine, guanfacine, and 
clonidine are the non-stimulants ( Faraone et al., 2015 ). The 
same drugs are used across the lifespan in clinical prac- 
tice, but only methylphenidate, lisdexamfetamine, and ato- 
moxetine are ofﬁcially approved for treatment of ADHD 
in childhood and adulthood in most European countries 
( Ramos-Quiroga et al., 2013 ). Unsurprisingly, there have 
been many more clinical trials evaluating the efﬁcacy and 
safety of these drugs in children than in adults ( Faraone 
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Table 1 Reported effect sizes (standardised mean difference) from meta-analysis for studies of treatment efﬁcacy for ADHD 
core symptoms in childhood and adulthood. 
Treatment and age-group Treatment type Effect size Reference 
Childhood: pharmacological 
treatment 
Methylphenidate 0.72 Faraone and Buitelaar (2010) 
Amphetamines 0.99 Faraone and Buitelaar (2010) 
Atomoxetine 0.64 Schwartz and Correll (2014) 
Guanfacine 0.63 Hirota et al. (2014) 
Clonidine 0.44 Hirota et al. (2014) 
Childhood: non-pharmacological 
treatment 
Omega-3 0.16 Sonuga-Barke et al. (2013) 
Diets 0.42 Sonuga-Barke et al. (2013) 
Neurofeedback 0.21 Hodgson et al. (2014) 
Multimodal psychosocial 0.09 Hodgson et al. (2014) 
Working memory training −0.02 −0.20 Cortese et al. (2015) ; Hodgson 
et al. (2014) 
Behaviour modiﬁcation −0.03 Hodgson et al. (2014) 
Parent training −0.51 Hodgson et al. (2014) 
Self-monitoring −5.91 Hodgson et al. (2014) 
School-based −0.26 −0.16 Hodgson et al. (2014) ; Richardson 
et al. (2015) 
Adulthood: pharmacological 
treatment 
Methylphenidate 0.42 −0.72 Castells et al. (2011b; Epstein 
et al. (2014 
Amphetamines 0.72 −1.07 Castells et al. (2011a) ; Fridman 
et al. (2015) 
Atomoxetine 0.38 −0.60 Asherson et al. (2014) ; Fridman 
et al. (2015) 
Adulthood: non-pharmacological 
treatment 
Cognitive-behavioural therapy 0.43 −1.0 Jensen et al. (2016) ; Knouse et al. 
(2017) ; Young et al. (2016) 
Mindfulness-based therapies 0.53 −0.66 Cairncross and Miller (2016) 
and Buitelaar, 2010; Fridman et al., 2015 ). Nevertheless, 
randomised, placebo-controlled clinical trials and meta- 
analyses convincingly show the effectiveness and safety of 
both stimulant and non-stimulant drugs for ADHD also in 
adults ( Epstein et al., 2014; Fridman et al., 2015 ) ( Table 1 ). 
The National Institute for Health and Clinical Excellence 
(NICE) guidelines recommend pharmacotherapy as ﬁrst- 
line treatment for adult ADHD (NICE, 2018 ) and consider 
methylphenidate as the ﬁrst choice for the treatment of 
adults, based on available meta-analytical evidence. Ap- 
parent differences in the effect size for methylphenidate 
across the lifespan are likely due to different dosing reg- 
imens applied in the clinical trials. Doses around 1 mg/kg 
of methylphenidate are correlated with better efﬁcacy, yet 
are rarely achieved in studies of adult patients. Regard- 
ing amphetamines or atomoxetine, the situation is similar; 
highest doses are related with best efﬁcacy. Another fac- 
tor that may explain the discrepancies in effect sizes is 
the presence of comorbid disorders. As an example, stud- 
ies that included patients with SUDs have shown compar- 
atively smaller effect sizes. The inﬂuence of such comor- 
bidities on treatment outcome is not exclusively observed 
in pharmacological trials, the same is seen for studies of 
non-pharmacological treatments. 
In terms of drug treatment side effects, the most typi- 
cal are decreased appetite, sleep disturbance, headaches, 
drowsiness, tearfulness, abdominal discomfort, nausea and 
vomiting, irritability, mood changes, constipation, fatigue, 
sedation, and increased blood pressure and pulse. Delays 
in height and weight are relatively minor with stimulants, 
often appear to attenuate with time, and seem not to af- 
fect ultimate height and weight in adulthood ( Fredriksen 
et al., 2013 ). The cardiovascular safety of stimulant med- 
ications and atomoxetine has been a subject of debate over 
many years. It is quite surprising that this controversy occurs 
for drugs such as methylphenidate, which have been on the 
market for over 50 years. Cohort studies, however, did not 
ﬁnd an increase in serious cardiovascular events following 
ADHD medications in children or adults, although both stim- 
ulants and atomoxetine were found associated with slight 
increases in heart rate and blood pressure ( Cooper et al., 
2011 ). 
Public concerns that stimulant treatment in childhood 
and adolescence may increase SUDs in adulthood seem un- 
substantiated. A comprehensive meta-analysis of long-term 
studies indicates comparable outcomes between children 
with and without medication treatment history for any sub- 
stance use and abuse or dependence outcome across all sub- 
stance types ( Hamshere et al., 2013 ); accordingly, Scandina- 
vian registry studies ( Chang et al., 2014b; Dalsgaard et al., 
2014 ) found that ADHD medication was not associated with 
increased rate of substance abuse; if anything, the data sug- 
gested a long-term protective effect on substance abuse 
( Chang et al., 2014b ) (see below). 
Research of pharmacotherapy in adults with ADHD is still 
largely lacking, especially with respect to clinical trials 
Developmental trajectories of ADHD 1067 
comparing different treatments (pharmacological or psy- 
chological) head to head as done in a pioneering study 
( Philipsen et al., 2015 ). At the same time, it is necessary to 
improve the external validity of these studies. Most of the 
existing clinical trials in this area are the ones performed 
to reach indication for adults for a particular drug. These 
studies used very restrictive inclusion and exclusion crite- 
ria, rarely reﬂecting real-life patients. A second area, in 
which more research is needed, is the systematic assess- 
ment of the efﬁcacy and safety of ADHD treatment in the 
presence of comorbid disorders, especially psychosis. Fi- 
nally, it is known that around 30% of ADHD patients do not 
respond to currently available treatments ( Faraone et al., 
2015 ). It is therefore important to investigate new pharma- 
cological targets beyond the dopaminergic and noradrener- 
gic systems, preferably including new knowledge on the bi- 
ological pathways involved in ADHD aetiology (see below). 
One line of evidence comes from a trial of low dose cannabi- 
noids, which found moderate to large effects on core ADHD 
symptoms in the absence of adverse effects; this study im- 
plicates the cannabinoid system as a potential new target 
for drug development ( Cooper et al., 2017 ). 
It is important to highlight the positive impact of ADHD 
treatment on aspects of daily functioning. Although initial 
studies were disappointing regarding the longer-term ef- 
fects of treatment ( Molina et al., 2009 ), the studies from 
Scandinavian registries impressively document positive out- 
comes of treatment, as discussed below. 
In addition to pharmacotherapy, several non- 
pharmacological approaches are used in the control and 
management of ADHD across the lifespan ( Table 1 ). In many 
countries, for children and adolescents with mild ADHD, 
non-pharmacological interventions are the ﬁrst-line treat- 
ment. In moderate or severe cases, the recommendation is 
to combine non-pharmacological treatment and drug treat- 
ment ( Faraone et al., 2015 ). Thus far, non-pharmacological 
treatments in childhood have demonstrated lesser efﬁcacy 
in reducing ADHD core symptoms than ADHD drugs ( Sonuga- 
Barke et al., 2013 ), but may have important beneﬁts for 
co-occurring comorbidities and behavioural problems. In 
fact, only free fatty acid supplementation and exclusion 
of artiﬁcial food colour from the diet demonstrated sig- 
niﬁcant beneﬁcial effects on ADHD core symptoms during 
childhood in a rigorous meta-analysis, although the effects 
were relatively small ( Chronis et al., 2006 ; Nutt et al., 
2007; Philipsen, 2012; Sonuga-Barke et al., 2013; Young 
et al., 2015 ). Although cognitive-behavioural therapy (CBT) 
approaches have not been proven efﬁcacious in children 
( Sonuga-Barke et al., 2013 ), the ﬁrst studies have reported 
that individual CBT ( Antshel et al., 2014 ) and group CBT 
( Vidal et al., 2015 ) could be effective treatments for 
adolescents with ADHD. 
Of particular importance is the transition from child- 
hood to adult services, requiring continuation of both med- 
ical and psychological support ( Nutt et al., 2007 ). As in- 
dicated above, for adults, pharmacological treatment is 
the recommended ﬁrst choice. Group CBT has been proven 
to beneﬁt adults with ADHD ( Solanto et al., 2010 ), but 
one study showed that highly structured group interven- 
tion did not outperform individual clinical management 
with unstructured support with regard to the core ADHD 
symptoms ( Philipsen et al., 2015 ). Promising ﬁndings also 
raise the possibility of mindfulness-based interventions as 
an effective treatment for ADHD symptoms ( Cairncross and 
Miller, 2016; Hepark et al., 2015 ). For other types of non- 
pharmacological treatments, such as neurofeedback, more 
evidence for efﬁcacy from randomised clinical trials with 
blinded assessment is necessary for both adolescents and 
adults ( Cortese et al., 2016 ). 
6. Disease outcome with and without 
treatment 
Assessment of disease outcome in ADHD requires longitu- 
dinal study designs, which are generally scarce. As a re- 
sult, also the knowledge about the role of treatment during 
the different phases of life in such outcomes is still patchy. 
Some clinically-based studies of high quality that have fol- 
lowed up pre-adolescents with ADHD into adulthood are al- 
ready available and have been instrumental in documenting 
the disease outcomes of ADHD in different aspects of life. 
Those include academic, occupational, and social aspects 
as well as morbidity and mortality. It has been shown that 
ADHD is associated with academic outcomes, such as poor 
academic performance (e.g., lower grade point average and 
increased rates of grade retention) ( Galera et al., 2009 ) and 
lower rates of high-school graduation and post-secondary 
education ( Galera et al., 2009; Klein et al., 2012; Man- 
nuzza et al., 1993 ). ADHD is also associated with negative 
occupational outcomes such as unemployment ( Biederman 
et al., 2006; Klein et al., 2012 ), having trouble keeping 
jobs ( Barkley et al., 2006; Biederman et al., 2006 ), ﬁnan- 
cial problems ( Barkley et al., 2006; Klein et al., 2012 ), 
and work incapacity in terms of sickness absence ( Kleinman 
et al., 2009; Secnik et al., 2005 ). Those studies have also 
shown that individuals with ADHD are at increased risk for 
poor social outcomes such as high rates of separation and 
divorce ( Biederman et al., 2006; Klein et al., 2012 ), resi- 
dential moves ( Barkley et al., 2006 ), and early parenthood 
( Barkley et al., 2006 ). 
In terms of mortality, several studies from Scandinavia 
have explored the association of ADHD with mortality and 
which factors are likely to increase mortality. These stud- 
ies have used information from national registers in Swe- 
den and Denmark that have been linked using a unique 
person identiﬁer. A Danish register-based study has found 
that ADHD is associated with signiﬁcantly increased mortal- 
ity rates, and that the excess mortality in ADHD is mainly 
driven by deaths from unnatural causes, especially acci- 
dents ( Dalsgaard et al., 2015b ). Other register-based stud- 
ies have conﬁrmed that individuals with ADHD are at in- 
creased risk for serious transport accidents ( Chang et al., 
2014a ), and also show increases in criminality ( Dalsgaard 
et al., 2013; Lichtenstein et al., 2012 ) and suicidal be- 
haviour ( Ljung et al., 2014 ), which are severe negative out- 
comes in their own right and could contribute to the in- 
creased mortality. 
Systematic reviews of the long-term disease outcomes of 
treated versus untreated ADHD are somewhat inconsistent. 
This is partly because long-term observational studies are 
often limited by a lack of data about treatment compliance 
and can be confounded by indication, since more severe 
cases will be more likely to be treated. A systematic review 
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of randomised controlled trial open-label extension stud- 
ies and naturalistic studies of adults with ADHD concluded 
that ADHD medications have long-term beneﬁcial effects 
and are well tolerated, but that more longitudinal studies 
of long duration need to be performed ( Fredriksen et al., 
2013 ). A second systematic review of both childhood and 
adult studies found that ADHD individuals left untreated had 
poorer long-term outcomes compared to treated individ- 
uals in several major categories including academic, anti- 
social behaviour, driving, non-medicinal drug use/addictive 
behaviour, obesity, occupation, services use, self-esteem, 
and social function outcomes, but that treatment did not 
result in normalisation ( Shaw et al., 2012 ). In contrast, a 
third systematic review of placebo-controlled discontinua- 
tion studies and prospective long-term observational stud- 
ies concluded that ADHD medication reduced ADHD symp- 
toms and impairments, but that there was limited and in- 
consistent evidence for long-term medication effects on im- 
proved social functioning, academic achievement, employ- 
ment status, and psychiatric comorbidity ( van de Loo-Neus 
et al., 2011 ). Long-term placebo controlled trials would be 
needed to allow deﬁnite conclusions, yet those are almost 
impossible to conduct in real life. 
Pharmaco-epidemiological analyses of large-scale 
databases, such as the national registers in Scandinavia, 
are an alternative source of information about potential 
(long-term) effects of ADHD medication on important 
disease outcomes. A large register-based Swedish study 
of adults with ADHD found that treatment with ADHD 
medication signiﬁcantly reduces the risk for criminality 
( Lichtenstein et al., 2012 ). Another Swedish register-based 
study found that adult males with ADHD had a 58% reduced 
risk of serious trafﬁc accidents in periods receiving treat- 
ment, compared with periods without treatment ( Chang 
et al., 2014a ). This was conﬁrmed in a recent study based 
on individuals with ADHD from a large insurance claims 
database, which found similar results in a US setting and 
also among females ( Chang et al., 2017 ). Three addi- 
tional pharmaco-epidemiological studies in children and 
adolescents, using data from a Danish record linkage of 
national registers ( Dalsgaard et al., 2015a ), a Hong Kong 
electronic medical records database ( Man et al., 2015 ), and 
a German insurance database ( Mikolajczyk et al., 2015 ), 
have further extended such ﬁndings to these age groups. 
A Danish register-based study showed that treatment with 
ADHD medication reduced the risk for injuries by up to 43% 
and emergency ward visits by up to 45% in children with 
ADHD ( Dalsgaard et al., 2015a ). 
The pharmaco-epidemiological studies can also help clar- 
ify the potential role of medication in causing morbidity. 
For example, two register-based studies of adolescents and 
adults with ADHD suggest that the co-occurrence of ADHD 
and suicidal behaviour is due to shared familial risk fac- 
tors ( Ljung et al., 2014 ), rather than to harmful effects 
of ADHD medications ( Chen et al., 2014 ). A recent study 
in a self-controlled case series also suggests that the ob- 
served elevation of suicide attempt risk after medication 
initiation is not causally related to the effects of stimu- 
lants ( Man et al., 2017 ). In this study, the incidence of 
suicide attempt was higher in the period immediately be- 
fore the start of stimulant treatment. The risk remained 
elevated immediately after the start of stimulant treat- 
ment and returned to baseline levels during continuation of 
stimulant treatment. Furthermore, the apparent increase 
in SUD risk in patients treated with stimulants, as discussed 
above, seems to be due to familiality rather than medica- 
tion effects. The previous concerns that stimulants could 
lead to an increase in SUDs could not be conﬁrmed by the 
pharmaco-epidemiological studies; these studies rather sug- 
gest a reduction in SUDs following medical treatment of 
ADHD ( Chang et al., 2014b; Skoglund et al., 2015 ). Another 
register-based study from Sweden suggests that ADHD med- 
ication does not increase the risk of later depression; also in 
this case, medication was associated with a reduced risk for 
subsequent and concurrent depression ( Chang et al., 2016 ). 
7. Changes in cognitive and neuroimaging 
proﬁles across the lifespan 
In addition to a lifespan perspective on phenotypic and out- 
come parameters in ADHD, also the dynamics across life in 
biological markers and risk factors for the disorder need 
to be understood better. ADHD is associated with several 
cognitive impairments and brain alterations, both in child- 
hood and in adulthood. Cognitive deﬁcits in ADHD encom- 
pass both higher-level, effortful cognitive functions (e.g., 
inhibitory control, visuo-spatial and verbal working mem- 
ory, sustained attention) and lower-level, potentially more 
automatic cognitive processes (e.g., temporal information 
processing and timing, vigilance, intra-individual variabil- 
ity, reward processing) ( Karalunas et al., 2014; van Lieshout 
et al., 2013; Willcutt et al., 2005 ). Meta-analyses of cogni- 
tive studies in children establish ADHD to be associated with 
poorer performance on tasks measuring inhibition, work- 
ing memory, planning, and vigilance ( Huang-Pollock et al., 
2012; Willcutt et al., 2005 ). ADHD is also associated with 
lower IQ scores ( Frazier et al., 2004 ). In addition, more re- 
cent studies, including meta-analyses, indicate a strong as- 
sociation of ADHD with reaction time variability (RTV), cap- 
turing lapses in attention ( Frazier-Wood et al., 2012; Karalu- 
nas et al., 2014; Kuntsi et al., 2010 ). Studies of adults with 
ADHD reveal overall similar patterns of cognitive impair- 
ments as found in children and adolescents ( Coghill et al., 
2014; Frazier-Wood et al., 2012; Hervey et al., 2004; Kuntsi 
et al., 2010; Mostert et al., 2015; Mowinckel et al., 2015; 
Sonuga-Barke et al., 2010 ). 
Structural and functional neuroimaging studies have doc- 
umented abnormalities in brain anatomy and function in 
individuals with ADHD ( Cortese et al., 2012; Frodl and 
Skokauskas, 2012; Greven et al., 2015 ). Meta-analyses of 
magnetic resonance imaging (MRI) studies show smaller vol- 
umes in the ADHD brain, most consistently in the basal gan- 
glia ( Frodl and Skokauskas, 2012; Hoogman et al., 2017 ). 
This is important considering the key role of basal ganglia 
in cognitive deﬁcits typically observed in ADHD, like reward 
processing. In particular, smaller globus pallidus, putamen, 
caudate nucleus, nucleus accumbens, amygdala, and hip- 
pocampus, but also smaller total intracranial volume, were 
found in children with ADHD, while in adults with ADHD, 
the subcortical volume reductions were less pronounced 
( Hoogman et al., 2017 ). A smaller anterior cingulate 
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cortex volume had been found earlier ( Frodl and 
Skokauskas, 2012 ). One relatively large study further re- 
ported reductions in total brain and total grey matter vol- 
ume in children, adolescents, and adults with ADHD, but no 
alterations in white matter volumes ( Greven et al., 2015 ) 
(but also see Onnink et al., 2015 ). Functional abnormali- 
ties are documented by a meta-analysis of 55 task-based 
functional MRI (fMRI) studies ( Cortese et al., 2012 ), report- 
ing that children with ADHD show a hypoactivation in the 
fronto-parietal and ventral attentional networks involved 
in executive function and attention, and a hyperactiva- 
tion in the sensorimotor network and default-mode network 
(DMN), involved in lower-level cognitive processes. Adult 
ADHD is, instead, mostly associated with a hypoactivation 
in the fronto-parietal system and a hyperactivation in the 
visual network, dorsal attention network, and DMN ( Cortese 
et al., 2012 ). Atypical brain activity has further been re- 
ported using EEG. For example, children and adults with 
ADHD show alterations in event-related potential (ERP) ac- 
tivity of attentional allocation, inhibition, preparation and 
error processing during cognitive tasks ( Albrecht et al., 
2013; Cheung et al., 2016; Geburek et al., 2013 ), and in 
quantitative EEG frequency power, mostly increased power 
of low frequency activity, during resting state ( Kitsune 
et al., 2015 ). 
Overall, cross-sectional studies indicate that many cog- 
nitive and brain abnormalities are associated with ADHD in 
both children and adults, although some differences have 
also been observed between age groups. Looking at the de- 
velopmental trajectories of cognitive, neuroanatomical and 
neurofunctional alterations in ADHD across the lifespan, it 
is important to examine whether cognitive and brain ab- 
normalities (1) show an age-independent, consistent asso- 
ciation with ADHD across the lifespan; (2) are predictors 
in childhood of later ADHD outcome; (3) can differentiate 
between individuals with persistent ADHD (from here on 
“ADHD persisters”) and individuals who have remitted from 
ADHD over time (from here on “ADHD remitters”). 
As for point (1), prospective longitudinal studies with re- 
peated assessments of ADHD and cognitive measures are 
needed to conﬁrm cross-sectional studies suggestive of sim- 
ilar impairments across the lifespan. Such studies to date, 
mostly focusing on higher-level cognitive functions using 
IQ tests, executive functioning and attentional tasks, show 
that impairments tend to persist from childhood to adoles- 
cence and early adulthood in ADHD persisters ( Biederman 
et al., 2009; Cheung et al., 2016; Hinshaw et al., 2007; 
McAuley et al., 2014 ). Fewer prospective longitudinal stud- 
ies have investigated the developmental association be- 
tween ADHD and lower-level cognitive impairments, such 
as intra-individual variability measured with RTV. The three 
largest studies conducted to date on RTV, using motor tim- 
ing and attentional paradigms, indicate persisting impair- 
ments both from middle to late childhood ( Vaughn et al., 
2011 ) and from childhood to adolescence/early adulthood in 
ADHD persisters ( Cheung et al., 2016; Thissen et al., 2014 ). 
However, in one of these studies the RTV impairment dur- 
ing a motor timing task did not persist in the oldest group of 
adults investigated, aged 22 years and above ( Thissen et al., 
2014 ). Other longitudinal studies have used smaller samples 
( Doehnert et al., 2010; Doehnert et al., 2013 ), not distin- 
guished between persisters and remitters ( Doehnert et al., 
2013; Mofﬁtt et al., 2015 ), or used different control groups 
in childhood and at follow up ( McAuley et al., 2014 ), making 
comparability to the above ﬁndings less clear. These stud- 
ies showed that deﬁcits in visual processing, vigilance, in- 
hibition, and IQ may continue in adult age ( Mofﬁtt et al., 
2015 ), while continuity of RTV impairments were observed 
from childhood to adulthood ( Doehnert et al., 2013 ), but 
not in adolescence ( Doehnert et al., 2010; McAuley et al., 
2014 ). 
Among neuroimaging studies, longitudinal studies us- 
ing multiple assessments from childhood to adulthood are 
scarce, and have mainly examined neuroanatomical abnor- 
malities with MRI. Available MRI studies consistently show 
that smaller brain volumes and morphometric abnormal- 
ities persist over time in ADHD persisters re-assessed in 
adolescence and early adulthood ( Castellanos et al., 2002; 
Shaw et al., 2006; Shaw et al., 2013 ). For example, de- 
velopmental abnormalities in cortical thinning have been 
observed in the medial and dorsolateral prefrontal cortex 
(components of networks supporting attention, cognitive 
control, and the DMN), which resulted in a pattern of non- 
progressive deﬁcit in persistent ADHD from childhood to 
young adulthood ( Shaw et al., 2013 ). Cortical thinning has 
also been found in ADHD in the medial and superior pre- 
frontal and precentral regions, especially for ADHD individu- 
als with worse clinical outcome: the ADHD group followed a 
similar developmental trajectory to control individuals from 
initial assessments in childhood to ﬁnal assessments in ado- 
lescence, but with reductions of cortical thickness at all as- 
sessments ( Shaw et al., 2006 ). Atypical developmental pat- 
terns of brain anatomy in individuals with persistent ADHD 
have been reported for subcortical regions and the cere- 
bellum ( Castellanos et al., 2002; Mackie et al., 2007; Shaw 
et al., 2014 ). Another study found divergent developmental 
trajectories from age 4 through 19 years for ADHD persisters 
and control individuals in the basal ganglia from childhood 
to adulthood: the ADHD group showed a smaller surface area 
in childhood and a progressive atypical contraction com- 
pared to the control group, which instead showed an expan- 
sion with age ( Shaw et al., 2014 ). A similar developmental 
trajectory was found for cerebellar volume, where individ- 
uals with persistent ADHD showed decreases in volume from 
childhood to adolescence/young adulthood, which were not 
observed in control individuals ( Mackie et al., 2007 ). Further 
MRI studies have examined the development of the corpus 
callosum and cortical surface area and gyriﬁcation ( Gilliam 
et al., 2011; Shaw et al., 2011 ), but without distinguish- 
ing between persistent and remittent ADHD at follow up, 
which makes the ﬁndings less informative. Little data exist 
on the continuity of functional brain alterations in ADHD. 
A small-scale longitudinal EEG study (n = 11 young adults 
with ADHD) reported that, among ERP impairments related 
to attentional allocation, inhibition, and response prepara- 
tion observed in childhood during a cued continuous per- 
formance test (CPT), only deﬁcits in response preparation 
were associated with ADHD in adulthood ( Doehnert et al., 
2013 ), without differentiating between persistent and re- 
mittent ADHD at follow up. 
The prediction of future ADHD outcome (remis- 
sion/persistence) based on early cognitive and neural im- 
pairments measured in childhood within an ADHD sample 
(point 2) is important for early identiﬁcation of those at 
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risk for worse long-term outcomes ( van Lieshout et al., 
2013 ), with an eye on optimising treatment. Studies ex- 
amining such prediction at short term indicate that impair- 
ments in early childhood in executive functions, especially 
inhibition and working memory, and in IQ predict ADHD 
symptoms in later childhood ( Berlin et al., 2003; Brocki 
et al., 2007; Campbell and von Stauffenberg, 2009; Kalff
et al., 2002 ), whereas RTV during a CPT does not ( Vaughn 
et al., 2011 ). Studies investigating clinical outcomes of 
ADHD persistence/remission with follow up in adolescence 
and adulthood have obtained inconsistent results. More re- 
cent follow-up studies of children with ADHD suggest that 
RTV and working memory across different tasks in child- 
hood may predict ADHD symptoms and/or functional im- 
pairment in adolescents and young adults, even when con- 
trolling for childhood ADHD symptoms ( Sjowall et al., 2015; 
van Lieshout et al., 2016a ). This is inconsistent with re- 
sults of studies examining persistence/remission of ADHD as 
later outcome, which found no evidence for association of 
aggregated measures of executive function, sustained at- 
tention, inhibition, working memory, and RTV in childhood 
and ADHD persistence/remission in adolescence and adult- 
hood ( Biederman et al., 2009; Cheung et al., 2015b; Mick 
et al., 2011 ). In a follow-up study, IQ was the only cognitive 
measure in childhood which predicted later ADHD persis- 
tence/remission, while measures of working memory (digit 
span backward), sustained attention (omission errors), inhi- 
bition (commission errors) and RTV from reaction-time and 
go/no-go tasks did not ( Cheung et al., 2015b ). The predic- 
tive value of IQ has been replicated in two other samples 
of young adults ( Agnew-Blais et al., 2016; Gao et al., 2015 ), 
but not in a third sample ( Francx et al., 2015b ). The only 
study to date to examine the predictive value of childhood 
brain activity on adult ADHD outcome indicated that resting- 
state EEG measures in the theta and beta bands predict 
ADHD persistence/remission ( Clarke et al., 2011 ), especially 
in frontal regions implicated in ADHD. 
As for point (3), the identiﬁcation of cognitive and neural 
processes underlying the trajectories of persistence and re- 
covery from childhood-onset ADHD during the transition to 
adulthood may further contribute to the prevention of nega- 
tive long-term outcomes. It has been hypothesised that the 
persistence of ADHD would be predicted by the degree of 
maturation and improvement over time in higher-level cog- 
nitive function, and lower-level cognitive functions would 
be linked to the presence of ADHD in childhood irrespec- 
tive of later clinical status ( Halperin and Schulz, 2006 ). In 
a follow-up study of almost 100 individuals with childhood 
ADHD assessed with both cognitive performance and EEG 
actigraph measures (mean age at follow up 18.30, SD 1.60), 
ADHD remitters did not differ from controls in higher-level 
cognitive functions (e.g. working memory and commission 
errors), but were still impaired in measures associated with 
lower-level cognitive processes (RTV and perceptual sensi- 
tivity) and ankle movement level ( Halperin et al., 2008 ). 
The latter ﬁnding was supported by a second study in the 
same sample, where RTV did not distinguish ADHD remit- 
ters from persisters, both of whom were impaired compared 
to controls ( Bedard et al., 2010 ). Other studies, however, 
have not found an association between ADHD remission and 
improvements in executive functioning ( Biederman et al., 
2009 ), interference control ( Pazvantoglu et al., 2012 ), and 
response inhibition ( McAuley et al., 2014 ). Working mem- 
ory impairments in young adults diagnosed with ADHD in 
adolescence compared to controls have also been observed 
regardless of whether they still met an ADHD diagnosis 
( Roman-Urrestarazu et al., 2016 ). Further studies found, 
across different cognitive tasks, that cognitive- EEG mea- 
sures of preparation, intra-individual variability (RTV), vig- 
ilance, and error processing (mostly reﬂecting lower-level 
cognitive functions) differentiated ADHD remitters from 
persisters assessed in adolescence and young adulthood 
( Cheung et al., 2016; James et al., 2017; Michelini et al., 
2016a ). Cognitive and brain activity measures of executive 
control of inhibition, working memory, and conﬂict moni- 
toring (largely reﬂecting higher-level cognitive functions) 
were not sensitive to persistence/remission of the disor- 
der ( Cheung et al., 2016; Michelini et al., 2016a ). As such, 
these studies may suggest that (“lower-level”) preparation- 
vigilance – instead of higher-level – cognitive functions may 
be markers of ADHD recovery, following the symptom level 
at follow up. 
Large-scale neuroanatomical studies also found evidence 
of differences between ADHD persisters and remitters in 
adolescents and adults in measures of brain volume and 
structural connectivity. ADHD remitters have shown a slower 
rate of cortical thinning from childhood to adulthood com- 
pared to persisters, such that brain dimensions may be 
more similar to those of control individuals in frontal and 
parietal regions with age ( Shaw et al., 2006; Shaw et al., 
2013 ). Structural connectivity impairments in the left corti- 
cospinal tract, implicated in the control of voluntary move- 
ments, have been reported in adolescents and young adults 
with childhood ADHD with persistent hyperactive-impulsive 
symptoms compared to individuals with greater symptom 
improvements over time and control individuals ( Francx 
et al., 2015b ). In white matter tracts connecting vari- 
ous regions related to sensorimotor and higher-level cog- 
nitive functions, however, both ADHD persisters and remit- 
ters showed impairments in adulthood compared to controls 
( Cortese et al., 2013 ). Developmental pathways of brain 
functioning may also show potential abnormalities, as sug- 
gested by studies of adolescents with a diagnosis of ADHD 
in childhood, but limited evidence is available to date. Two 
studies of adolescents and young adults reported increased 
resting-state fMRI connectivity in ADHD remitters compared 
to controls in the executive control network, with inter- 
mediate connectivity proﬁles in persisters ( Francx et al., 
2015a ), and increased EEG connectivity during an executive 
control task in both ADHD remitters and persisters ( Michelini 
et al., 2017 ). Other small-scale fMRI studies further suggest 
that thalamic and cortical activation during response prepa- 
ration ( Clerkin et al., 2013 ) and caudate activation during 
working memory performance (Roman-Urrestarazu et al., 
2016) may be reduced in both ADHD persisters and remit- 
ters. Instead, lower functional correlation between poste- 
rior cingulate and medial prefrontal cortices (major com- 
ponents of the DMN) during rest ( Mattfeld et al., 2014 ), 
lower connectivity between the thalamus and prefrontal re- 
gions during response preparation ( Clerkin et al., 2013 ), and 
lower activations in areas of the prefrontal cortex involved 
in reward processing ( Wetterling et al., 2015 ) may distin- 
guish ADHD persisters from remitters and controls. 
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Overall, despite some inconsistencies between studies, 
some convergence for cognitive and neuroimaging markers 
of ADHD persistence and remission is starting to emerge. For 
example, the majority of studies to date show that impair- 
ments in executive function do not distinguish ADHD remit- 
ters and persisters ( Biederman et al., 2009; Cheung et al., 
2016; McAuley et al., 2014 ; Michelini et al., 2016a , 2017 ; 
Pazvantoglu et al., 2012 ). A particularly critical issue, likely 
explaining some of the discrepancies across studies, is vari- 
ability in the way the persistence and remission are deﬁned, 
as studies differ in the use of parent- or self-reports and 
on whether functional impairment is taken into account at 
follow-up assessments. However, there is a relatively low 
agreement between self- and parent-reports of ADHD in 
adolescents and young adults, and objective cognitive and 
neurophysiological data show lower agreement with ADHD 
outcome in adolescence and young adulthood based on self- 
report than on parent-report ( Du Rietz et al., 2016 ). 
8. The role of genetic and environmental 
risk factors and their interplay in ADHD across 
the lifespan 
While investigations into the dynamics of cognitive and neu- 
roimaging markers across life have gained traction, the re- 
search into lifespan aspects of underlying risk factors for 
ADHD is still very much in its infancy. ADHD has a strong 
genetic component. Family studies have consistently shown 
familial clustering, with an ADHD relative risk of about 5- 
to 10-fold in ﬁrst-degree relatives of probands with ADHD 
( Biederman, 2005; Biederman et al., 1990; Franke et al., 
2012 ). Twin studies show heritability estimates between 70% 
and 80%, and the underlying genetic architecture of ADHD 
appears similar across the different core symptom dimen- 
sions and gender ( Faraone et al., 2005; Larsson et al., 2014; 
Nikolas and Burt, 2010 ). Consistent evidence supports sta- 
bility in the ADHD heritability across the lifespan estimated 
using the same informant across ages and cross-informant 
approaches ( Brikell et al., 2015; Chang et al., 2013; Kuntsi 
et al., 2005 ). 
Given the multifactorial, polygenic nature of ADHD, ge- 
netic research has mainly focused on common variants 
through hypothesis-driven candidate gene association stud- 
ies (CGAS) and genome-wide association studies (GWAS) 
with case-control or family-based designs. These designs 
consist on observational studies in which the frequencies 
of speciﬁc common genetic variants within candidate genes 
for ADHD or a genome-wide set of polymorphisms are com- 
pared between affected (cases) and unaffected (controls) 
individuals or between affected subjects and their relatives. 
Several linkage studies have also been performed. They 
allow genetic mapping of complex traits showing famil- 
iar aggregation by assessing the co-segregation of the dis- 
ease phenotype with sequence variants across the genome. 
More recently, genetic studies in ADHD have also focused 
on rare variation (allele frequency < 0.05) through copy- 
number variant (CNV) analyses, which inspect alterations in 
genomic segments of more than 1Kb in length, and exome 
chip analysis and whole-exome sequencing, targeting point 
mutations or small indels. These investigations have shown 
converging evidence for common biological pathways un- 
derlying ADHD, which highlights that both common and rare 
genetic variants account for a signiﬁcant proportion of the 
genetic susceptibility to the disorder ( Martin et al., 2015b; 
Stergiakouli et al., 2012; Zayats et al., 2016 ). 
To date, seven genome-wide linkage scans have been 
performed in ADHD. Although very little overlap was ob- 
served between analyses, different genetic loci potentially 
involved in ADHD have been found on chromosomes 5p13, 
14q12, and 17p11, and a meta-analysis of ADHD linkage 
studies conﬁrmed a locus on chromosome 16 ( Zhou et al., 
2008 ). Only few positional candidate genes have, however, 
been identiﬁed from these linkage scans, e.g. DIRAS2 ( Reif 
et al., 2011 ) and LPHN3 ( Arcos-Burgos et al., 2010 ). Also, 
although hundreds of CGAS have been reported, only a few 
ﬁndings have been consistently replicated across studies. 
These studies have focused primarily on genes involved in 
neurotransmission, particularly in the monoaminergic path- 
ways. Serotonin and dopamine receptors and transporters 
are the most extensively studied and replicated across pop- 
ulations ( Franke et al., 2012; Gizer et al., 2009; Hawi et al., 
2015 ). Almost all studies were performed in children, and 
none of the resulting candidate genes can be considered as 
established. One of the few genes tested thoroughly in both 
children and adults is the dopamine transporter, and intrigu- 
ingly, opposite alleles were associated with childhood and 
adulthood ADHD ( Franke et al., 2010 ). 
GWAS on ADHD have been completed in nine indepen- 
dent datasets ( Anney et al., 2008; Franke et al., 2009; Hin- 
ney et al., 2011; Lasky-Su et al., 2008; Mick et al., 2010; 
Neale et al., 2008; Sanchez-Mora et al., 2015; Stergiak- 
ouli et al., 2012; Yang et al., 2013; Zayats et al., 2015 ), 
three of them focusing on the persistent form of the dis- 
order ( Lesch et al., 2008; Sanchez-Mora et al., 2015; Za- 
yats et al., 2015 ). Although none of them, nor two meta- 
analyses on several of these datasets ( Neale et al., 2010; 
van Hulzen et al., 2016 ), reported genome-wide signiﬁ- 
cance, the integration of top ﬁndings from the different 
studies showed enrichment of genes related to neurobi- 
ological functions potentially relevant to ADHD, such as 
neurite outgrowth, central nervous system development, 
neuronal development, differentiation and activity, neuron 
migration, synaptic transmission, axon guidance, Calcium- 
activated K + channels, FGFR ligand binding, and activa- 
tion or potassium channels, among others ( Mooney et al., 
2016; Sanchez-Mora et al., 2015; Yang et al., 2013; Zayats 
et al., 2015 ). For the ﬁrst time, a very recent GWAS meta- 
analysis in 20,183 ADHD cases and 35,191 controls, includ- 
ing children and adults from 12 datasets, reported genome- 
wide signiﬁcant hits in 12 independent loci that include 
genes involved in neurodevelopmental processes, such as 
FOXP2 or DUSP6, and evolutionarily conserved genomic re- 
gions ( Demontis et al., 2017 ). Limited overlap exists be- 
tween results of GWAS and previous CGAS or linkage studies, 
and a separate analysis for the persisting versus remitting 
forms of ADHD is still lacking. Thus, the genetic architecture 
underlying the lifespan trajectory of ADHD is still largely 
obscure. 
Although each of the ADHD-associated variants appears 
to account for a small proportion of the variance in ADHD 
symptoms, SNPs were estimated to account for 10% to 28% 
of the heritability of the disorder ( Anttila et al., 2018; De- 
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montis et al., 2017; Cross-Disorder Group of the Psychiatric 
Genomics Consortium, 2013 ). These studies also highlight 
substantial genetic overlap between the ADHD genetic back- 
ground and ADHD-related traits, other psychiatric and neu- 
rological disorders or behavioural-cognitive traits, includ- 
ing positive correlations with major depressive disorder, mi- 
graine, obesity, and smoking, as well as negative correla- 
tion with educational outcomes and childhood IQ ( Anttila 
et al., 2018; Demontis et al., 2017; Cross-Disorder Group 
of the Psychiatric Genomics Consortium, 2013 ). In addi- 
tion to GWAS, under the hypothesis that ADHD can be ex- 
plained by the ensemble of genetic markers of small ef- 
fect, polygenic risk score approaches have emerged to as- 
sess whether, when considered “en masse”, ADHD com- 
mon risk variants also contribute to different ADHD-related 
phenotypes. These ﬁndings provided evidence that poly- 
genic risk for ADHD predicts hyperactivity-impulsivity and 
inattention traits in the general population, as well as 
autism spectrum disorder-related traits and conduct disor- 
der ( Hamshere et al., 2013; Martin et al., 2014 ). Again, none 
of these studies considered the lifespan perspective. 
Research on rare variants involved in ADHD points at a 
greater burden of large CNVs ( > 100 kb or > 500 kb) in chil- 
dren or adolescents with the disorder ( Martin et al., 2015b; 
Stergiakouli et al., 2012; Williams et al., 2010 ) and in adults 
with ADHD ( Lesch et al., 2011; Ramos-Quiroga et al., 2014 ), 
and also shows enrichment of ADHD-related CNVs at loci 
previously associated with neurodevelopmental disorders, 
such as autism and schizophrenia ( Thapar et al., 2016 ). Ad- 
ditional evidence from exome sequencing supports the in- 
volvement of rare variants (minor allele frequency (MAF) 
of < 1%) in individuals with ADHD at different age ranges. 
Although the study of a pedigree with several affected indi- 
viduals failed to identify causal rare variants for ADHD ( Lyon 
et al., 2011 ), rare de novo missense variants were found in 
brain-expressed genes in children with sporadic ADHD ( Kim 
et al., 2017 ) and novel putative functional rare variants in 
the BDNF were identiﬁed in children and adolescents with 
ADHD ( Hawi et al., 2017 ). Rare missense and disruptive vari- 
ants were also identiﬁed through whole-exome sequencing 
or exome chip analyses in adult ADHD ( Zayats et al., 2016 ). 
Overall, while it is well-established that ADHD is a highly 
heritable condition with a complex genetic architecture, 
more research is needed to identify the speciﬁc genetic un- 
derpinnings of the disorder and its persistence into adult- 
hood. In addition to risk factors stably involved in ADHD 
throughout the lifespan, the susceptibility to ADHD persis- 
tence may be a dynamic process, with speciﬁc genetic in- 
ﬂuences acting at different developmental stages ( Chang 
et al., 2013; Kuntsi et al., 2005 ). Thus, different sets of 
genes, and even different alleles at a given risk locus, 
could be involved in the differentiation between persist- 
ing and remitting forms ( Franke et al., 2012; Kuntsi et al., 
2005 ) and inﬂuence the disorder and associated cognitive 
deﬁcits differently according to age (gene by age interac- 
tions) ( Thissen et al., 2015 ). To our knowledge, all genetic 
studies that have approached the problem of the potential 
differential genetic load of ADHD in persisting versus remit- 
ting cases so far have simply compared children and adults 
with ADHD. Although these reports describe genetic speci- 
ﬁcities in age groups ( Franke et al., 2012; Ribases et al., 
2009 ), they may be subject to false-negative ﬁndings, as 
the comparison is between persistent cases and a sample 
of children likely to be a heterogeneous group of individu- 
als in which the disorder will persist or remit into adulthood. 
Longitudinal designs constitute an alternative approach that 
may provide insights into the role of genes in the persistence 
of ADHD across the lifespan. 
9. Environmental risk factors and 
gene-by-environment (GxE) interactions 
One explanation for the discrepancy between high heri- 
tability estimates for ADHD and the scarcity of replicable 
gene-disorder associations could be that expression of spe- 
ciﬁc genes is conditional on epigenetic programming. Such 
programming is inﬂuenced by both genetic code and envi- 
ronment of an individual, although the contribution of the 
environment to the aetiology of the disorder seems to be 
lower than that of heritable factors (with around 22% of 
ADHD variance explained by environmental factors ( Faraone 
et al., 2005; Nikolas and Burt, 2010 ). The concept of gene- 
by-environment (GxE) interaction is in line with epidemi- 
ologic studies revealing – in addition to the genetic risk 
– associations between ADHD and environmental adversity 
including pre- and peri-natal risk factors (maternal stress, 
smoking or alcohol consumption during pregnancy, low birth 
weight, prematurity), environmental toxins (organophos- 
phates, polychlorinated biphenyls, lead), unfavourable psy- 
chosocial conditions (severe early-childhood deprivation, 
maternal hostility) and nutritional factors ( Faraone et al., 
2015 ). It is likely that the heritability estimates for ADHD 
based on twin research are inﬂated by GxE interactions 
( Purcell, 2002 ), which may also account in part for some in- 
consistent ﬁndings of genetic association. Accordingly, sev- 
eral studies support the inﬂuence of genetic variants on ef- 
fects of environmental risk factors for ADHD ( Franke and 
Buitelaar, 2018 ), with interactions found e.g. between DRD4 
and exposure to prenatal smoking ( Pluess et al., 2009 ), 
SLC6A3/DAT1 and maternal use of alcohol during pregnancy 
( Brookes et al., 2006 ), institutional deprivation ( Kumsta 
et al., 2010 ) psychosocial adversity ( Laucht et al., 2007 ), 
SLC6A4 / 5HTT and psychosocial stress ( Muller et al., 2008 ), 
MAOA and negative parenting behaviour ( Li and Lee, 2012 ), 
and ADGRL3 / LPHN3 and maternal stress during pregnancy 
( Choudhry et al., 2012 ). 
Most of the environmental factors that are considered 
to increase ADHD and comorbid disorder susceptibility act 
prenatally, suggesting that exposure to environmental risks 
would have more impact if occurring during a critical devel- 
opmental period (for a review, see Mill and Petronis, 2008; 
Spiers et al., 2015 ). Although it should be kept in mind 
that risk factors associated with a disorder are not neces- 
sarily causal ( Rutter, 2007 ), there is now evidence to sug- 
gest that early-life exposure to smoking, alcohol, and illicit 
drug use as well as suboptimal nutrition or the changes in 
microbiome composition can permanently affect transcrip- 
tional regulation through epigenetic alterations, and this is 
thought to contribute to the long-lasting consequences on 
offspring health ( Loche and Ozanne, 2016 ). Foetal, perina- 
tal, and adolescent periods are the developmental periods 
of highest phenotypic plasticity, contributing largely to de- 
velopmental programming, and the epigenome is sensitive 
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to environmental challenges applied during these critical 
windows of development. Various risk factors that usually 
accompany behavioural disorders seem to be involved in 
these epigenetic modiﬁcations, especially early-life stress 
including trauma, abuse, and neglect. As there is prelim- 
inary evidence for a role of diet or lifestyle in ADHD, di- 
etary changes, like the elimination or addition of certain 
nutrients, are being explored as a possible way to modify 
symptoms ( Lange, 2017 ). While nutrition and lifestyle, as 
well as environmental adversity in general, are thought to 
be potent epigenetic modiﬁers, complex interactions among 
food components, environmental toxins, or drugs of abuse 
and DNA methylation, histone modiﬁcations and epigenetic- 
related RNA-based mechanisms lead to dynamic regulation 
of gene expression that controls the neural cell phenotype 
and brain function ( Robison and Nestler, 2011 ). A consid- 
erable challenge to research on the human epigenome is, 
however, the tissue and cell speciﬁcity of epigenetic modiﬁ- 
cation. As brain tissue from ADHD patients is not available, 
research on epigenetic mechanisms has to rely on acces- 
sible material (e.g. blood or buccal cells) as a proxy for 
the brain. Nevertheless, there is evidence that epigenetic 
research in humans is feasible, and ﬁrst studies, focusing 
on both potential risk genes ( Heinrich et al., 2017; van Mil 
et al., 2014 ) and the entire epigenome ( Walton et al., 2017; 
Wilmot et al., 2016 ), conﬁrm links between epigenetic mod- 
iﬁcation of genes and ADHD. 
A pioneering study on ADHD epigenetics was a whole- 
epigenome screening of two independent samples in boys 
with ADHD by Wilmot et al. (2016) . It provided evidence 
for an involvement of gene-sets and pathways related to in- 
ﬂammatory processes as well as modulation of monoamine 
and cholinergic transmission. Two genes, encoding VIPR2 
and MYT1L (mutations cause intellectual disability, autism), 
were conﬁrmed in the replication sample. Walton et al. 
(2017) reported that DNA methylation at birth differenti- 
ated ADHD-related trajectories in a population-based co- 
hort across multiple genomic locations implicating e.g. 
genes coding for SKI (involved in neural tube development), 
ZNF544 (previously linked to ADHD), and ST3GAL3 (muta- 
tions cause intellectual disability), although none of these 
genes maintained an association with ADHD trajectories at 
age 7 years. Together, these studies – some in small co- 
horts – provide initial insight into the epigenetic background 
of ADHD, underscoring the relevance of differential DNA 
methylation in genes related to monoaminergic, cholinergic 
and GABAergic transmitter system function and neurodevel- 
opmental processes that play a role in the formation, mat- 
uration, and plasticity of distinct brain networks. 
10. Discussion and future directions 
In this review, we aimed to provide an overview of the cur- 
rent knowledge about ADHD across the lifespan. We covered 
the major phenotypic and biological issues related to this 
disorder, which is a prominent cause of psychiatric morbid- 
ity and impairment in both childhood and adulthood. We dis- 
cussed developmental trajectories in core phenotype deﬁni- 
tion, comorbidity, cognitive and brain structural/functional 
markers, as well as treatment trajectories, outcomes, and 
genomic markers. Our review shows that beyond research 
into the core symptoms of ADHD, information is still very 
patchy, and relatively little is known about developmental 
trajectories from childhood into adulthood for most of the 
issues of interest. This deﬁnes priorities in the coming years 
for research of phenotypic issues, treatment and prediction 
of outcome, as well as our understanding of the biological 
underpinnings of ADHD. 
In all areas of our investigation into the ADHD literature, 
the absence of studies in the elderly is highly apparent. Old 
age is the current blind spot of ADHD research, which has 
to be factored in when interpreting all the data presented 
above. This lack of knowledge limits the possibility to per- 
form a review of the complete lifespan, as most available 
studies deal with ADHD in children – even 50 years after the 
ﬁrst studies showed that ADHD also exists in adults and can 
continue from childhood to adulthood ( Wood et al., 1976 ). 
Beyond mid-adulthood, hardly any information on ADHD can 
be found. 
An important additional caveat of current literature is the 
limited availability of longitudinal studies with a careful and 
repeated, detailed characterisation of participants across 
different phases of the lifespan regarding terms of deep 
clinical phenotyping as well as biomarkers. Such work is es- 
sential to chart the trajectory of ADHD symptoms over the 
lifetime and will answer important questions about the in- 
terplay of ADHD disposition with environmental conditions. 
Those studies are urgently needed for clinical cohorts as 
well as the general population, and should include broad 
assessment batteries of disease phenotypes and treatments, 
quantitative behavioural measures, cognitive tasks and neu- 
roimaging, as well as repeated biomaterial collection. Some 
existing population studies, like MoBA ( Magnus et al., 2016 ), 
ALSPAC ( Martin et al., 2015a ), the Dunedin Study ( Mofﬁtt 
et al., 2015 ), and LifeLines ( Stolk et al., 2008 ) and in partic- 
ular more recent large-scale initiatives like the UK Biobank 
( Clarke et al., 2017 ) may provide a template for such work. 
Pressing questions for research in such cohorts can be de- 
ﬁned in terms of the phenotypic deﬁnition of ADHD: 
(1) Only in such longitudinal cohorts the relation of apparent 
adult-onset ADHD to the neurodevelopmental form of the 
disorder can be deﬁned: are these different disease en- 
tities, with different aetiologies and (co)morbidity pro- 
ﬁles, or can they be different subtypes/presentations of 
the same, overarching disorder? To study this question, 
one needs also to enrol children with mental disorders 
other than ADHD and sub-threshold ADHD symptoms. 
(2) Is the persistent form of ADHD really persistent, or do 
ADHD symptoms over time ﬂuctuate with varying inten- 
sity, thus creating suffering and burden only in speciﬁc 
life phases, e.g. characterised by high life stress or high 
demands for self-management ( Grevet et al., 2006 )? Per- 
sistent ADHD, after all, might not be as trait-like as it is 
assumed ( Karam et al., 2017 ), which might obscure its 
detection. 
(3) There are only a few studies on ADHD remitters. How- 
ever, this particular group brings up important questions: 
which are the resilience factors that protect against per- 
sistence? Are there differential genetic factors that have 
a role in remission versus persistence? What about en- 
vironmental factors and GxE phenomena? What is the 
brain’s developmental trajectory? Clues that help to an- 
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swer these questions might translate into clinical prac- 
tice to improve the outcome of patients, and thus ac- 
cording studies should be prioritised. 
(4) Developmental trajectories of comorbidity proﬁles and 
cognitive functioning across the lifespan: as we have 
reviewed above, ADHD is characterised by extensive 
comorbidity in childhood and adulthood. However, the 
comorbidity proﬁles of child and adult ADHD change 
and only partly overlap. Clinical longitudinal studies are 
needed to understand onset and changes in comorbid- 
ity. Recent ﬁndings from large genetic studies as well 
as register-based studies show that comorbidity is of- 
ten based on shared familial and genetic factors (e.g. 
Ghirardi et al., 2017; Cross-Disorder Group of the Psy- 
chiatric Genomics Consortium, 2013 ). 
(5) Cognitive functioning, brain structure/function, and the 
contribution of genetic and environmental risk factors 
across the lifespan: overall, cognitive and neuroimag- 
ing studies to date converge in indicating that most im- 
pairments persist when ADHD persists from childhood to 
later assessments. Yet, most existing studies are cross- 
sectional and have used samples in young or middle 
adulthood only. Large longitudinal studies are needed, 
also including assessments of older age groups, to fully 
characterise the developmental trajectories of ADHD- 
related cognitive and brain impairments across the lifes- 
pan. In addition, since some of the cognitive and neural 
alterations observed in ADHD are non-speciﬁc, but rather 
shared with other disorders (e.g. autism and bipolar dis- 
order) Rommelse et al., 2011; Michelini et al., 2016b , 
2018 ), future research should take into account comor- 
bid symptoms when examining the persistence of impair- 
ments. In terms of genetic and environmental risk fac- 
tors, we need to clarify the contribution of individual 
factors across the lifespan. Also, recent work indicates 
that there is limited speciﬁcity in the genetic contribu- 
tion to ADHD ( Demontis et al., 2017 ) and other psychi- 
atric disorders (e.g. Anttila et al., 2018 ). In fact, it ap- 
pears that part of the genetic contribution to psychiatric 
disorders is due to a general psychopathology factor (or 
“p-factor”) (e.g. Neumann et al., 2016 ). How these ﬁnd- 
ings relate to comorbidity and disease outcome in ADHD 
is another important area of future research. 
(6) Finally, prediction of disease outcome is an area of re- 
search that can directly inﬂuence treatment decisions 
in daily clinical practice. Cognitive, electrophysiologi- 
cal, and neuroimaging markers associated with childhood 
ADHD persist into adulthood, but show variable trajecto- 
ries reﬂecting both delayed maturation and within-group 
differences. Findings suggest a pattern of corresponding 
biomarkers that predict remission versus persistence of 
ADHD symptoms in adolescence and adulthood. However, 
to move forward towards potential clinical applications 
of these markers as a means to identify those childhood 
and adolescent cases with ADHD that are at high risk for 
persistent ADHD, prediction parameters at the individual 
level have to be examined. Importantly, the predictive 
power/accuracy of currently identiﬁed biomarkers is in- 
dividually low. Future studies should therefore explore 
whether combining markers from different cognitive and 
imaging domains as well as (epi)genetic approaches may 
improve prediction. Future longitudinal and clinical stud- 
ies should address these questions while using sophisti- 
cated approaches, like normative modelling and multi- 
variate pattern recognition ( Wolfers et al., 2015 ). While 
ADHD outcome is mostly deﬁned as persistence of the 
clinical diagnosis or symptoms, studying outcomes re- 
lated to educational performance and adulthood func- 
tionality might also be of importance for the quality of 
life of patients. 
The questions raised above reach far beyond mere aca- 
demic interest, as respective answers will immediately im- 
pact on ADHD treatment. For instance, timing of treatment 
is an essential issue, as we are only about to begin to un- 
derstand the long-term effects of pharmacological ADHD 
treatment regarding outcome (educational, socio-economic 
and, most importantly, health, also regarding comorbid con- 
ditions). To address this, however, we need granular lon- 
gitudinal studies, initiated in childhood and followed up 
long-term. A tightly linked question is how adolescents can 
be kept in treatment – or at least in mental health ser- 
vices – during the transitional period, thereby preventing 
the “transition gap” and potentially the development of co- 
morbid disorders such as depression or SUD. On the other 
hand, a waxing and waning pattern of ADHD symptoms and 
related burden of disease in speciﬁc life situations might 
allow for interval treatment, and especially addressing the 
role of resilience in the interaction of life stress and ADHD 
disposition might unleash a huge potential for psychother- 
apy. More research into persistence within and across differ- 
ent age-ranges is therefore urgently needed. Beyond these 
“traditional” approaches, novel treatments, such as non- 
invasive brain stimulation, neurofeedback, and nutritional 
interventions, should be assessed for their lifespan effects. 
Within this framework of long-term treatment effects, pre- 
diction has also to be factored in. If ADHD persistence or 
development of comorbidity could reliably be foreseen, this 
would dramatically alter the way ADHD is treated over the 
lifespan, opening up a perspective for precision medicine. 
Most likely, predictive approaches will be multimodal (in- 
tegrating genetics, proteomics, neuroimaging, and granular 
ecological momentary assessment (EMA) of behavioural pat- 
terns), but also require biomarker studies on disease trajec- 
tories of the lifespan. 
In terms of understanding the risk factors underlying 
ADHD, which might be linked to such predictive markers, 
important progress has been made in the areas of environ- 
mental and genetic risk factors in recent years. In particular, 
the latter one has been enabled by technological progress 
as well as the formation of large, international collabo- 
rations, like the Psychiatric Genomics Consortium ( Cross- 
Disorder Group of the Psychiatric Genomics Consortium, 
2013 ). Still, acknowledging the small effect sizes of most in- 
dividual genetic risk factors for ADHD, much larger samples 
will be needed in the future to identify a sufﬁcient number 
of the underlying genes to tease out the most strongly in- 
volved (and potentially druggable) biological pathways con- 
tributing to ADHD. An excellent development in this area 
is the increasing availability of biosamples linked to popu- 
lation registers, starting with the Danish iPSYCH Initiative 
( Demontis et al., 2017 ). This will likely allow us to reach 
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sample sizes of over 100,000 patients in the next 5 years. 
In addition, the recent demonstration of the strong genetic 
overlap of clinically diagnosed ADHD and population ADHD 
scores ( Demontis et al., 2017 ) will contribute to a strong rise 
in sample availability and the number of ADHD loci identi- 
ﬁed in the coming years. Critical windows for environmental 
risk factors across the lifespan are already understood quite 
well. However, while we know that partly different sets of 
genetic factors contribute to ADHD onset and persistence 
( Chang et al., 2013 ), the lifespan perspective has yet to be 
taken in genetics research and is only rarely addressed. The 
availability of register-data and population samples also in- 
creases our prospects of improving our knowledge about dif- 
ferences in the contribution of different genetic risk factors 
to ADHD across the lifespan. 
More than 1000 genes/genomics regions may contribute 
to neurodevelopmental disorders like ADHD. Many of those 
genes/regions can be expected to contain several inde- 
pendent risk loci. How informative the identiﬁcation of all 
of those will be for our understanding of disease mecha- 
nisms and potential new treatment routes has recently been 
questioned by a paper discussing “omnigenic” diseases and 
traits ( Boyle et al., 2017 ). In their paper, the authors ar- 
gue that the most informative genetic markers may come 
from studies of rare genetic variants, as more or less all 
genes expressed in a certain tissue can be expected to make 
small contributions to a disease related to this tissue ( Boyle 
et al., 2017 ). The role of rare variants in ADHD across the 
lifespan is currently virtually unexplored (although an ex- 
ome sequencing study is in the ﬁnal stages of analysis), 
and awaits the upcome of affordable genome sequencing 
approaches. 
Lastly, epigenetics research offers great opportunities 
to integrate genetic and environmental risk in ADHD. Also 
here, only ﬁrst steps have been made towards exploring 
the involvement of aberrant epigenetic patterning in ADHD. 
As discussed above, these steps are hampered by the tis- 
sue speciﬁcity of epigenetic modiﬁcations, leading to un- 
certainty about the predictive value of proxy tissues like 
blood and saliva, which are the only accessible tissues 
available in large samples. Changes in epigenetic proﬁles 
over time, like those needed to explore lifespan changes 
in the ADHD phenotype/outcome, might be more infor- 
mative in those proxy tissues, but this hypothesis awaits 
testing. 
In conclusion, ADHD is the prototypic example of a 
neurodevelopmental disorder starting early in life and 
developing with a highly variable trajectory. While in 
some cases it might be the entry point into a negative, 
burdensome trajectory, other patients may remit and even 
transform some deﬁcits into adaptive behaviours, living 
highly successful lives. The latter suggests that there 
is potential for improvement in many ADHD patients, if 
recognised early on and receiving optimal treatment. To 
clarify the course, to identify those at risk of unfavourable 
outcome and to provide tailored treatment, longitudinal, 
granular, and multimodal studies are clearly needed. While 
we appreciate that this poses a challenge, we are conﬁdent 
that such an endeavour would – just like the ﬁght against 
HIV three decades ago – pay off in every respect to improve 
the life of many patients. 
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